Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP894667.RA5J4ccAjlJ0gZP0kcf8NKU7d73JuTpD8OVUSf3drAPdI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP894667.RA5J4ccAjlJ0gZP0kcf8NKU7d73JuTpD8OVUSf3drAPdI130_assertion type Assertion NP894667.RA5J4ccAjlJ0gZP0kcf8NKU7d73JuTpD8OVUSf3drAPdI130_head.
- NP894667.RA5J4ccAjlJ0gZP0kcf8NKU7d73JuTpD8OVUSf3drAPdI130_assertion wasGeneratedBy ECO_0000203 NP894667.RA5J4ccAjlJ0gZP0kcf8NKU7d73JuTpD8OVUSf3drAPdI130_provenance.
- NP894667.RA5J4ccAjlJ0gZP0kcf8NKU7d73JuTpD8OVUSf3drAPdI130_assertion wasDerivedFrom befree-20140225 NP894667.RA5J4ccAjlJ0gZP0kcf8NKU7d73JuTpD8OVUSf3drAPdI130_provenance.
- NP894667.RA5J4ccAjlJ0gZP0kcf8NKU7d73JuTpD8OVUSf3drAPdI130_assertion SIO_000772 18593924 NP894667.RA5J4ccAjlJ0gZP0kcf8NKU7d73JuTpD8OVUSf3drAPdI130_provenance.
- NP894667.RA5J4ccAjlJ0gZP0kcf8NKU7d73JuTpD8OVUSf3drAPdI130_assertion evidence source_evidence_literature NP894667.RA5J4ccAjlJ0gZP0kcf8NKU7d73JuTpD8OVUSf3drAPdI130_provenance.
- NP894667.RA5J4ccAjlJ0gZP0kcf8NKU7d73JuTpD8OVUSf3drAPdI130_assertion description "[The PDGFR and c-Raf inhibitor sorafenib (BAY 43-9006; Bayer Pharmaceuticals), currently approved for treatment of advanced renal cell cancer, inhibits both basal and PDGFRbeta-mediated ERK1/2 and AKT activity and decreases cell proliferation in human schwannoma cells, suggesting that this drug constitutes a promising tool to treat schwannomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP894667.RA5J4ccAjlJ0gZP0kcf8NKU7d73JuTpD8OVUSf3drAPdI130_provenance.